Abramson Cancer Center at Penn Medicine: Pancreatic Neoplasms trials

The registry lists 15 Pancreatic Neoplasms studies with Abramson Cancer Center at Penn Medicine as lead sponsor. 3 are open to participants now and 3 have results posted.

Early Phase 1 2Phase 1 7Phase 2 2No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• FTT PET/CT in Pancreatic Neuroendocrine TumorsRecruitingNCT07114939Phase 1
• Collection of Circulating Biomarkers in Pancreatic CancerRecruitingNCT05743049
• Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic RiskRecruitingNCT02478892
• A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic CancerTerminatedNCT03519308Early Phase 1Results posted
• Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based TherapyTerminatedNCT03140670Phase 2Results posted
• A Pilot Study to Evaluate Radiotherapy-Induced Anti-Tumor Immunity in Metastatic Carcinoma of the PancreasCompletedNCT01985958Not applicableResults posted
• Evaluating an Alternative Clinical Genetics Cancer Care Deliver ModelCompletedNCT03934606
• A Study of Entinostat and FOLFOX in Subjects With Pancreatic AdenocarcinomaWithdrawnNCT03760614Phase 1
• In Vivo PARP-1 Expression With 18F-FTT PET/CT in Pancreatic CancerTerminatedNCT03492164Early Phase 1
• A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic CancerTerminatedNCT03300921Phase 1
• Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic CancersCompletedNCT02639026Phase 1
• Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic CarcinomaCompletedNCT02588443Phase 1
• Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic CarcinomaCompletedNCT01456585Phase 1
• Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic CancerCompletedNCT00602602Phase 2
• Tipifarnib and Radiation Therapy in Treating Patients With Unresectable Locally Advanced Pancreatic CancerCompletedNCT00077519Phase 1